Keywords: otc, famotidine, japan, merck, co, chugai, joint-venture
OTC Famotidine In Japan
Article | 12 June 1997
Merck & Co and Chugai's joint-venture company in Japan, Chugai MSD,has gained rights to comarket Yamanouchi Pharmaceutical's famotidine over-the-counter for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
